News
ATHA
0.3040
-1.78%
-0.0055
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 6d ago
Weekly Report: what happened at ATHA last week (0602-0606)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 06/05 12:08
Athira Pharma Holds Annual Stockholders Meeting
TipRanks · 06/02 20:37
Weekly Report: what happened at ATHA last week (0526-0530)?
Weekly Report · 06/02 09:27
Weekly Report: what happened at ATHA last week (0519-0523)?
Weekly Report · 05/26 09:27
Weekly Report: what happened at ATHA last week (0512-0516)?
Weekly Report · 05/19 09:25
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105
TipRanks · 05/13 15:10
Athira Pharma To Present Data From Phase 1 Clinical Trial Of ATH-1105 In Healthy Volunteers At 4Th Annual ALS Drug Development Summit
Benzinga · 05/13 15:02
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
Barchart · 05/13 10:00
Weekly Report: what happened at ATHA last week (0505-0509)?
Weekly Report · 05/12 09:26
Athira Pharma Reports Reduced Losses and Strategic Focus
TipRanks · 05/10 04:16
Athira Pharma GAAP EPS of -$0.23 beats by $0.01
Seeking Alpha · 05/09 20:31
Athira Pharma Q1 EPS $(0.23) Up From $(0.69) YoY
Benzinga · 05/09 20:08
ATHIRA PHARMA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PIPELINE AND BUSINESS UPDATES
Reuters · 05/09 20:05
Press Release: Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Dow Jones · 05/09 20:05
Press Release: Athira Pharma Reports First -2-
Dow Jones · 05/09 20:05
*Athira Pharma 1Q Loss/Shr 23c >ATHA
Dow Jones · 05/09 20:05
*Athira Pharma 1Q Loss $9.15M >ATHA
Dow Jones · 05/09 20:05
Weekly Report: what happened at ATHA last week (0428-0502)?
Weekly Report · 05/05 09:25
More
Webull provides a variety of real-time ATHA stock news. You can receive the latest news about Athira Pharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ATHA
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. It has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.